Tilray Target of Unusually Large Options Trading (NASDAQ:TLRY)

Tilray Inc (NASDAQ:TLRY) was the target of some unusual options trading on Friday. Traders acquired 72,984 call options on the stock. This is an increase of 61% compared to the typical volume of 45,257 call options.

Insider Activity

In related news, CFO Carl A. Merton purchased 26,000 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The stock was purchased at an average cost of $1.36 per share, with a total value of $35,360.00. Following the completion of the acquisition, the chief financial officer now directly owns 26,000 shares in the company, valued at $35,360. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.87% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TLRY. JPMorgan Chase & Co. increased its position in Tilray by 32.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 432,031 shares of the company’s stock worth $760,000 after purchasing an additional 105,803 shares during the last quarter. Synovus Financial Corp increased its position in Tilray by 176.7% in the 3rd quarter. Synovus Financial Corp now owns 36,092 shares of the company’s stock worth $64,000 after purchasing an additional 23,046 shares during the last quarter. Barclays PLC increased its position in Tilray by 600.4% in the 3rd quarter. Barclays PLC now owns 204,144 shares of the company’s stock worth $359,000 after purchasing an additional 174,997 shares during the last quarter. Toronto Dominion Bank increased its position in Tilray by 454.5% in the 3rd quarter. Toronto Dominion Bank now owns 128,923 shares of the company’s stock worth $227,000 after purchasing an additional 105,671 shares during the last quarter. Finally, XTX Topco Ltd boosted its stake in shares of Tilray by 1,079.7% during the 3rd quarter. XTX Topco Ltd now owns 281,504 shares of the company’s stock worth $495,000 after acquiring an additional 257,641 shares in the last quarter. 9.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Roth Mkm dropped their price objective on Tilray from $2.00 to $1.75 and set a “neutral” rating for the company in a research report on Friday, October 11th.

Tilray Trading Down 5.5 %

Shares of TLRY stock opened at $1.37 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.57 and a current ratio of 2.47. The firm has a market capitalization of $1.24 billion, a PE ratio of -5.07 and a beta of 2.08. The stock has a fifty day moving average of $1.38 and a two-hundred day moving average of $1.62. Tilray has a 1 year low of $1.14 and a 1 year high of $2.97.

Tilray (NASDAQ:TLRY) last announced its earnings results on Thursday, October 10th. The company reported ($0.04) EPS for the quarter, meeting the consensus estimate of ($0.04). Tilray had a negative return on equity of 2.00% and a negative net margin of 26.79%. The business had revenue of $200.00 million during the quarter, compared to the consensus estimate of $218.70 million. During the same period in the prior year, the business posted ($0.10) earnings per share. Tilray’s revenue was up 13.0% compared to the same quarter last year. As a group, research analysts expect that Tilray will post -0.14 EPS for the current year.

About Tilray

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.